A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Clinical trial NCT03390504 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03390504
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-23
- Primary completion
- 2024-04-15
- Enrollment
- 629
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.